España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Daiichi Sankyo Co
DSNKY
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$27.92
-0.01000
-0.04%
At close: -
$27.79
-0.13
-0.47%
After Hours: Dec 19, 4:00 PM EDT
Get Report
Comment
Daiichi Sankyo Co (DSNKY) Forecast
News
Earnings
Daiichi Sankyo Co (DSNKY) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Daiichi Sankyo Co (OTC:DSNKY) Stock
Daiichi Sankyo Co Stock (OTC: DSNKY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, December 06, 2024
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
Vandana Singh
Reported Earlier, Daiichi Sankyo And AstraZen...
Benzinga Newsdesk
Tuesday, November 12, 2024
Daiichi Sankyo And AstraZeneca Submit New BLA...
Benzinga Newsdesk
Monday, November 11, 2024
Reported Sunday, Alteogen Secures Exclusive L...
Benzinga Newsdesk
Thursday, October 31, 2024
Daiichi Sankyo Co expects FY2024 GAAP EPS Gui...
Benzinga Newsdesk
Daiichi Sankyo Co Q2 EPS $0.22 Up From $0.14 ...
Benzinga Newsdesk
Monday, September 23, 2024
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
Vandana Singh
Tuesday, September 17, 2024
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Vandana Singh
Tuesday, September 10, 2024
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
Vandana Singh
Monday, September 09, 2024
Reported Saturday, Daiichi Sankyo And Merck's...
Benzinga Newsdesk
Monday, August 19, 2024
Daiichi Sankyo And AstraZeneca's ENHERTU Rece...
Benzinga Newsdesk
Wednesday, August 07, 2024
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
Surbhi Jain
Tuesday, August 06, 2024
Daiichi Sankyo, Merck Expand Partnership To C...
Benzinga Newsdesk
Tuesday, July 30, 2024
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Vandana Singh
Thursday, June 27, 2024
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
Vandana Singh
Monday, June 03, 2024
Reported Earlier, Daiichi Sankyo And AstraZen...
Benzinga Newsdesk
Tuesday, May 28, 2024
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Vandana Singh
Monday, April 29, 2024
Double Good News For AstraZeneca's Breast Cancer Drugs
Vandana Singh
Monday, April 08, 2024
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
Vandana Singh
Tuesday, April 02, 2024
Daiichi Sankyo And AstraZeneca's Datopotamab ...
Benzinga Newsdesk
Monday, February 19, 2024
Daiichi Sankyo And AstraZeneca Announced Earlier, BLA For Datopotamab Deruxtecan Accepted By FDA, Potential First TROP2 Directed ADC For Non-Squamous NSCLC After Prior Therapy
Charles Gross
Monday, January 29, 2024
Daiichi Sankyo And AstraZeneca's Supplemental...
Benzinga Newsdesk
Thursday, January 25, 2024
What's Going On With Pfizer Stock Today?
Vandana Singh
Wednesday, January 03, 2024
Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
Nabaparna Bhattacharya
Friday, December 22, 2023
The FDA Has Accepted And Granted Priority Rev...
Benzinga Newsdesk
Wednesday, December 20, 2023
Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
Surbhi Jain
Friday, October 20, 2023
Daiichi Sankyo And Merck Announce Collaborati...
Benzinga Newsdesk
Friday, September 22, 2023
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
Vandana Singh
AstraZeneca- Daiichi Sankyo's Datopotamab Der...
Benzinga Newsdesk
Monday, September 11, 2023
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Vandana Singh
AstraZeneca, Daiichi Sankyo's Datopotamab Der...
Benzinga Newsdesk
Friday, July 21, 2023
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
Vandana Singh
Tuesday, July 04, 2023
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Lara Goldstein
Monday, July 03, 2023
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
Vandana Singh
Datopotamab Deruxtecan Jointly Developed By D...
Benzinga Newsdesk
Tuesday, June 27, 2023
Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
Lara Goldstein
Monday, March 20, 2023
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
Vandana Singh
Monday, March 06, 2023
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Vandana Singh
Friday, January 13, 2023
Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
Vandana Singh
Monday, December 19, 2022
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
Vandana Singh
Friday, December 09, 2022
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
Vandana Singh
Wednesday, December 07, 2022
AstraZeneca-Daiichi Sankyo's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
Vandana Singh
Monday, November 14, 2022
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
Vandana Singh
Monday, October 31, 2022
Daiichi Sankyo Q2 Sales ¥327.50B Up From ¥280...
Benzinga Newsdesk
Wednesday, September 21, 2022
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
Vandana Singh
Monday, September 12, 2022
This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
Vandana Singh
Monday, August 15, 2022
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
Vandana Singh
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
Vandana Singh
Friday, August 12, 2022
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
Vandana Singh
Tuesday, August 09, 2022
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
Vandana Singh
Show More
